Persistent chemosensitivity to platinum and/or paclitaxel in metastatic endometrial cancer

Gynecologic Oncology

Volumn 73, Issue 3, 1999, Pages 422-423

  Markman, Maurie ^a   Kennedy, Alexander ^a   Webster, Kenneth ^a   Kulp, Barbara ^a   Peterson, Gertrude ^a   Belinson, Jerome ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; CHEMOSENSITIVITY; ENDOMETRIUM CANCER; FEMALE; HUMAN; HYSTERECTOMY; METASTASIS; PRIORITY JOURNAL; RECURRENT CANCER;

EID: 0033016653     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1999.5407     Document Type: Article

References (14)

1. Moore T D, Phillips P H, Nerenstone S R, Cheson B D. Systemic treatment of advanced and recurrent endometrial carcinoma: Current status and future directions. J Clin Oncol. 9:1991;1071-1088.
2. Ball H G, Blessing J A, Lentz S S, Mutch D G. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: A Gynecologic Oncology Group study. Gynecol Oncol. 62:1996;278-281.
3. Thigpen T, Blessing J, Homesley H, Malfetano J, DiSaia P, Yordan E. Phase III trial of doxorubicin +/- cisplatin in advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. Proc Am Soc Clin Oncol. 12:1993;261.
4. Rose P G. Endometrial carcinoma. N Engl J Med. 335:1996;640-649.
5. Fisher R I, DeVita V T, Hubbard S P, Simon R, Young R C. Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Ann Intern Med. 90:1979;761-763.
6. Batist G, Ihde D C, Zabell A, Lichter A S, Veach S R, Cohen M H, Carney D N, Bunn P A. Small-cell carcinoma of the lung: Reinduction therapy after late relapse. Ann Intern Med. 98:1983;472-474.
7. Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Lewis J L Jr. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 9:1991;389-393.
8. Gershenson D M, Kavanagh J J, Copeland L J, Stringer C A, Morris M, Wharton J T. Re-treatment of patients with recurrent epithelial ovarian cancer with cisplatin-based chemotherapy. Obstet Gynecol. 73:1989;798-802.
9. Rose P G, Fusco N, Fluellen L, Rodriguez M. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J Clin Oncol. 16:1998;1494-1497.
10. Hoskins P J, O'Reilly S E, Swenerton K D. The 'failure free interval' defines the likelihood of resistance to carboplatin in patient with advanced epithelial ovarian cancer previously treated with cisplatin: relevance to therapy and new drug testing. Int J Gynecol Cancer. 1:1991;205-208.
11. Gore M E, Fryatt I, Wiltshaw E, Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol. 36:1990;207-211.
12. Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Evidence that a "treatment-free interval of less than 6 months" does not equate with clinically defined platinum resistance in ovarian cancer or primary peritoneal carcinoma. J Ca Res Clin Oncol. 124:1998;326-328.
13. Markman M. "Recurrence within 6 months of platinum-therapy": An adequate definition of "platinum-refractory" ovarian cancer. Gynecol Oncol. 69:1998;91-92.
14. Markman M, Hoskins W. Responses to "salvage" chemotherapy in ovarian cancer: A critical need for precise definitions of the treated population. J Clin Oncol. 10:1992;513-514.